Subsequent Study. 3.14.1 During the Term and for a period of [*****] months thereafter, either Party shall have the option to propose amending this Agreement and the Related Agreements or negotiating a new agreement (a “Subsequent Study Agreement”), as appropriate, for the purpose of conducting a registration study for the Combination in the same indication as the Study (each a “Subsequent Study”) by sending a written proposal to the other Party. Company must offer Merck the option of participating in a Subsequent Study prior to entering into an agreement with a Third Party to conduct a registration study in the same indication and line of therapy as the Study of the Company Compound in concomitant and/or sequential administration with a PD-1 Antagonist.
Subsequent Study. (a) During the Term and for a period of *** after Study Completion, either Party shall have the option to propose amending this Agreement and the Related Agreements or negotiating a new agreement (the “Subsequent Study Agreement”), as appropriate, for the purpose of conducting follow-on studies for the Combination (each a “Subsequent Study”) by sending written notification of such proposal to the other Party.
Subsequent Study. 3.14.1 During the Term and for a period of * (*) months thereafter, either Party shall have the option to propose amending this Agreement and the Related Agreements or negotiating a new agreement (a “Subsequent Study Agreement”), as appropriate, for the purpose of conducting a registration study for the Combination in * as the Study (each a “Subsequent Study”) by sending a written proposal to the other Party. Company * prior to entering into *. *Confidential material redacted and filed separately with the Commission.
Subsequent Study. During the Term and for a period of [***] thereafter, either Party shall have the option to propose amending this Agreement (and the Related Agreements as necessary) or negotiating a new agreement, as appropriate, for the purpose of conducting a Subsequent Study. Neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement; provided, however, in the event this Agreement is amended or a new agreement is executed for the purpose of conducting a Subsequent Study, the Parties shall grant to each other a non-exclusive, worldwide, royalty-free, fully paid-up, transferable, and sublicensable license [***]. Notwithstanding such [***]License, in no event shall: [***].
Subsequent Study. During the Term and for a period of twelve (12) months thereafter, either Party shall have the option to propose amending this Agreement (and the Related Agreements as necessary) or negotiating a new agreement, as appropriate, for the purpose of conducting a Subsequent Study. During such time period, Collaborator must offer MSD the option of participating in a Subsequent Study no less than sixty (60) days prior to entering into an agreement with a Third Party to conduct a registrational study of the Collaborator Compound in combination with a PD-1 Antagonist in the same indication(s) and line(s) of therapy as the MSD Compound Study. Following receipt of a proposal for a Subsequent Study, the Parties shall negotiate in good faith the terms of such amendment or new agreement. Neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement; provided, however, in the event this Agreement is amended or a new agreement is negotiated for the purpose of conducting a Subsequent Study, the Parties shall grant to each other a non-exclusive, worldwide, royalty-free, fully paid-up, transferable, and sublicensable license to any Patent Controlled by a Party or its Affiliate that claims or covers the Combination and is not a Joint Patent under the amended Agreement or the new agreement solely for the purpose of: (i) conducting the Subsequent Study, (ii) researching and developing the Combination in the same indication as the Combination Arm during the term of the amended Agreement or the new agreement, and (iii) obtaining and promoting an initial or an updated label indication for the Combination in the same indication as the Combination Arm during the longer of the Term and the life of such Patents (“Freedom- to-Operate License”). Notwithstanding such Freedom-to-Operate License, in no event shall: (i) MSD have the right to exploit such licensed Patents to sell any Collaborator Class Compound, either alone or as part of a combination (including the Combination); or (ii) Collaborator have the right to exploit such licensed Patents to sell any PD-1 Antagonist, either alone or as part of a combination (including the Combination).
Subsequent Study. [***]. [***]
Subsequent Study. 3.14.1 ****.
Subsequent Study. 3.14.1 During the Term and for a period of * thereafter (the “Option Period”), either Party shall have the option to propose amending this Agreement and the Related Agreements or negotiating a new agreements , as appropriate (such amendment or new agreement, a “Subsequent Study Agreement”), for the purpose of conducting a registration study for the Combination in the same Indication(s) as the Study (each a “Subsequent Study”) by sending a written proposal to the other Party during the Option Period. During the Option Period, Intensity must offer MSD the option of participating in a Subsequent Study prior to entering into an agreement with a Third Party to conduct a registration study of the Intensity Compound in concomitant and/or sequential administration with a PD-1 Antagonist in the same Indication(s) as the Study. [***]
Subsequent Study. During the Term and for a period of [***] thereafter, either Party shall have the option to propose amending this Agreement (and the Related Agreements as necessary) or negotiating a new agreement, as appropriate, for the purpose of conducting a Subsequent Study. During such time period, Collaborator must offer MSD the option of participating in a Subsequent Study no less than [***] prior to entering into an agreement with a Third Party to conduct a registrational study of [***]. Following receipt of a proposal for a Subsequent Study, the Parties shall negotiate in good faith the terms of such amendment or new agreement. Neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement; provided, however, in the event this Agreement is amended or a new agreement is negotiated for the purpose of conducting a Subsequent Study, the Parties shall grant to each other a non-exclusive, worldwide, royalty-free, fully paid-up, transferable, and sublicensable license [***](“Freedom-to-Operate License”). Notwithstanding such Freedom-to-Operate License, in no event shall:[***].
Subsequent Study. 3.14.1. During either (i) the [ * ] and for a period of [ * ] thereafter, or (ii) the term of the Agreement and for a period of [ * ] thereafter, whichever is sooner, either Party shall have the option to propose amending this Agreement and the Related Agreements or entering into a new agreement for the purpose of an expansion of the Study to [ * ] (the “[ * ]”).
